NSCLC patients with KEAP1/NFE2L2/CUL3 mutations have significantly shorter time to treatment failure (TTF) and overall survival (OS) when treated with first-line chemotherapy [39]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.